Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3908693 | 0.77 | MEN1 (0.46) | ALDH1A1CHRNA7MAPT | |
| SCHEMBL11900726 | 0.76 | CXCR2 (0.51) | ALDH1A1MAPT | |
| SCHEMBL3981866 | 0.75 | MAPT (0.61) | ALDH1A1DHFRABL1BCRKCNH2 | |
| SCHEMBL3921096 | 0.75 | MAPT (0.52) | ALDH1A1MAPTEPHX2 | |
| SCHEMBL31047209 | 0.74 | RAPGEF4 (0.53) | ALDH1A1TDO2MAPT | |
| SCHEMBL27110704 | 0.74 | RAPGEF4 (0.53) | ALDH1A1TDO2MAPT | |
| SCHEMBL3194551 | 0.73 | MAPT (0.61) | ALDH1A1CHRNA7DHFRABL1BCR | |
| SCHEMBL1923201 | 0.73 | MAPT (0.61) | ALDH1A1CHRNA7DHFRABL1BCR | |
| SCHEMBL9070626 | 0.72 | MAPT (0.52) | CHRNA7DHFRABL1BCRMAPT | |
| SCHEMBL13198824 | 0.71 | SCN8A (0.44) | KCNH2SCN5ASCN9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974779-B2 | Piperidine derivatives as human papilloma virus inhibitors | VAXART, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180021318-A9 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | VAXART, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20170079968-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | AVIRAGEN THERAPEUTICS INC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9452991-B2 | Piperidine derivatives as human papilloma virus inhibitors | AVIRAGEN THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20120220633-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA | 2012-08-30 | — | — | US | disclosed |
| US-8207373-B2 | Benzoic acid derivatives as human papilloma virus inhibitors | ANACONDA PHARMA (FR) | 2012-06-26 | — | — | US | disclosed |
| US-20090209586-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170079968-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | POLI, VHL, EBNA1BP2 | ALDH1A1 452/4885CHRNA7 4776/4885TDO2 4822/4885 |
| US-20180021318-A9 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | POLI, VHL, EBNA1BP2 | ALDH1A1 452/4885CHRNA7 4776/4885TDO2 4822/4885 |
| US-20090209586-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | IDH3A, IDH1, CBR3 | ALDH1A1 123/4885CHRNA7 4203/4885TDO2 500/4885 |
| US-20120220633-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | IDH3A, CBR3, CBR1 | ALDH1A1 138/4885CHRNA7 3835/4885TDO2 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.